All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 10 November 20263 min read

Suraksha Diagnostic (SURAKSHA) Q2 FY27 Profit Surges 69% as Higher Test Prices Drive Margins

The diagnostic chain's Q2 profit grew faster than revenue, powered by a 19% rise in average revenue per test, though expansion costs are rising.

By Abhinav Singhvi, Founder & CEO Hexawealth · Created 10 November 2026

Suraksha Diagnostic's Q2 FY27 net profit soared 69% YoY to ₹14.95 crore. Revenue grew 26%, but the real story was a 390 bps margin expansion driven by higher-value tests and pricing power, even as interest costs surged on expansion-led debt.

For diagnostic chains, the path to profit lies in moving beyond simple blood tests. Suraksha Diagnostic’s September quarter shows it is succeeding, with profit surging 69% year-on-year to ₹14.95 crore. The leap came from charging more for each test, not just from running more of them.

Revenue rose 26% to ₹99.07 crore, continuing a steady climb. Profit growth far outpaced it, lifting the net profit margin to 15.1%, a 390-basis-point improvement from a year ago.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 78.73, Q3 FY26 77.69, Q4 FY26 81.41, Q1 FY27 87.64, Q2 FY27 99.07. Q2 FY26 8.83, Q3 FY26 7.24, Q4 FY26 6.16, Q1 FY27 12.84, Q2 FY27 14.95050100150200Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 78.73
  • Revenue (₹ Cr), Q3 FY26: 77.69
  • Revenue (₹ Cr), Q4 FY26: 81.41
  • Revenue (₹ Cr), Q1 FY27: 87.64
  • Revenue (₹ Cr), Q2 FY27: 99.07
  • Profit (₹ Cr), Q2 FY26: 8.83
  • Profit (₹ Cr), Q3 FY26: 7.24
  • Profit (₹ Cr), Q4 FY26: 6.16
  • Profit (₹ Cr), Q1 FY27: 12.84
  • Profit (₹ Cr), Q2 FY27: 14.95

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 78.73, Q3 FY26 77.69, Q4 FY26 81.41, Q1 FY27 87.64, Q2 FY27 99.07050100150200Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 78.73
  • Revenue (₹ Cr), Q3 FY26: 77.69
  • Revenue (₹ Cr), Q4 FY26: 81.41
  • Revenue (₹ Cr), Q1 FY27: 87.64
  • Revenue (₹ Cr), Q2 FY27: 99.07

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 8.83, Q3 FY26 7.24, Q4 FY26 6.16, Q1 FY27 12.84, Q2 FY27 14.9505101520Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26: 8.83
  • Profit (₹ Cr), Q3 FY26: 7.24
  • Profit (₹ Cr), Q4 FY26: 6.16
  • Profit (₹ Cr), Q1 FY27: 12.84
  • Profit (₹ Cr), Q2 FY27: 14.95

Net Profit Margin

Net Profit MarginQ2 FY26 11.2%, Q3 FY26 9.3%, Q4 FY26 7.6%, Q1 FY27 14.7%, Q2 FY27 15.1%0%5%10%15%20%Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Net Profit Margin, Q2 FY26: 11.2%
  • Net Profit Margin, Q3 FY26: 9.3%
  • Net Profit Margin, Q4 FY26: 7.6%
  • Net Profit Margin, Q1 FY27: 14.7%
  • Net Profit Margin, Q2 FY27: 15.1%
MetricCurrentQ2 FY27PreviousQ1 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
99.07YoY +26%
87.64
78.73
Profit (₹ Cr)
14.95YoY +69%
12.84
8.83
Net Profit Margin
15.1%YoY +35%
14.7%
11.2%

The engine behind the margin leap

Suraksha’s profit jump was not just about more patients. According to reports from scanx.trade, the average revenue per test rose 19% year-on-year to ₹427. Patient volumes grew 12%, but the higher-value service mix was the key driver.

This pricing power allowed the company to absorb rising costs. Total expenses grew 21%, slower than revenue, creating operating leverage. Management noted five new centres opened in the quarter, strengthening its West Bengal base.

The cost of funding growth

Expansion is not free. Interest expense surged 74% year-on-year to ₹4.84 crore, a direct result of higher borrowings to fund new hubs and spokes. StockFin.ai data shows borrowings rose from ₹6 crore in March 2025 to ₹130 crore by March 2026.

Live Chart

· SURAKSHA

(BSE)

ISIN: INE877V01027

This leverage is a deliberate trade-off. The company is investing ₹70-80 crore this year to reach 100 centres by FY28, as stated in its Q1 earnings call. The rising finance cost is the price for that future scale.

Can the pricing power last?

The outlook hinges on sustaining this premium. Management, cited by RealCase, revised its full-year growth guidance to over 40% and is confident in market tailwinds. The focus for the second half is on improving maturing centres and disciplined expansion.

The competitive landscape, however, is intense. National chains and online aggregators keep pricing pressure on routine tests. Suraksha’s recent success comes from climbing the value chain into more complex diagnostics where competition is thinner.

Key Points

  • Net profit margin expanded 390 basis points year-on-year to 15.1%, driven by a 19% increase in average revenue per test.
  • Interest expense jumped 74% as borrowings rose to fund an aggressive network expansion targeting 100 centres by FY28.
  • Management revised its full-year growth guidance upward, expressing confidence in sustained demand and its expansion strategy.

Hexa Perspective

Suraksha’s quarter is a clear case of operating leverage winning, for now. The 390 bps margin expansion shows the benefit of a richer service mix, a moat that discounters cannot easily breach. The catch is the 74% spike in interest cost, a direct line to its ₹70-80 crore annual capex plan.

The next few quarters will test whether new centres can ramp up quickly enough to keep profit growth ahead of the financing burden. If the average revenue per test holds, the model works. If competition forces a retreat on pricing, the leverage turns from fuel to weight.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Suraksha Diagnostic (SURAKSHA) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Suraksha Diagnostic's Q2 FY27 results?
Suraksha Diagnostic reported a consolidated net profit of ₹14.95 crore for Q2 FY27 (July-September 2026), a 69% increase year-on-year. Revenue from operations grew 26% to ₹99.07 crore, with the net profit margin expanding to 15.1%.
Why did Suraksha Diagnostic's Q2 FY27 profit jump 69%?
Profit surged primarily due to a richer service mix and strong pricing power. Reports from scanx.trade indicate the average revenue per test rose 19% year-on-year. This allowed profit to grow much faster than total expenses, which increased 21%.
What was Suraksha Diagnostic's net profit margin in Q2 FY27?
Suraksha Diagnostic's net profit margin was 15.1% in Q2 FY27, a significant expansion of 390 basis points from 11.2% in the same quarter last year. This improvement was driven by higher realisations per test.
Why did Suraksha Diagnostic's interest expense surge in Q2 FY27?
Interest expense rose 74% year-on-year to ₹4.84 crore due to higher borrowings taken to fund network expansion. Data from StockFin.ai shows borrowings increased substantially from ₹6 crore in March 2025 to ₹130 crore by March 2026 to support capex.
What is Suraksha Diagnostic's expansion plan and capex outlook?
Management aims to reach 100 centres by FY28. For FY27, the capex plan is around ₹70-80 crore, as stated in the Q1 earnings call. The company opened five new centres in Q2 and is expanding into newer states like Jharkhand and Tripura.
What was the management commentary after Suraksha Diagnostic's Q2 FY27 results?
Management revised its full-year growth guidance to over 40%, according to RealCase. The focus for H2 FY27 is on driving sustainable growth through the existing network, improving maturing centres, and pursuing disciplined expansion in new markets.
How did Suraksha Diagnostic's average revenue per test change in Q2 FY27?
Suraksha Diagnostic's average revenue per test increased by 19% year-on-year to ₹427 in Q2 FY27, up from ₹357 in Q2 FY26. This pricing power was a key contributor to the quarter's significant margin expansion.
What is Suraksha Diagnostic's debt level?
As per StockFin.ai analysis, Suraksha Diagnostic's borrowings rose to ₹130 crore as of March 2026, up sharply from ₹6 crore in March 2025. This increase in debt is funding the company's aggressive network expansion and capex plans.
Suraksha Diagnostic Q2 profit rises 69% to Rs 14.95 crore?
Yes, Suraksha Diagnostic's consolidated net profit for Q2 FY27 (September 2026 quarter) was ₹14.95 crore, a 69% increase from ₹8.83 crore in Q2 FY26. Revenue for the quarter stood at ₹99.07 crore.
Suraksha Diagnostic Q2FY27 Results: Net profit up 69% YoY to ₹14.95 crore?
Correct. For the quarter ended September 30, 2026, Suraksha Diagnostic reported a consolidated net profit of ₹14.95 crore, a 69% year-on-year increase. Consolidated revenue from operations was ₹99.07 crore, up 26% from the year-ago period.